Establishing a category defining clinical data solution to fuel innovation, enhance patient care, and improve operational efficiencies in healthcare
MRO Corp. (MRO), the leading clinical data exchange company in healthcare, announced today the acquisition of Q-Centrix Corp. (Q-Centrix), a leading enterprise clinical data management platform, enabling hospitals and health systems to turn fragmented clinical data into actionable information. This strategic combination positions MRO to further accelerate the exchange of clinical data throughout the healthcare ecosystem for providers, payers, life sciences and users of clinical data. The combined company services over 2,000 hospitals and health systems, more than 7,000 clinics, and nearly 250 payers. The financial terms of the transaction were not disclosed.
“At MRO, we believe there is tremendous untapped value in unlocking and leveraging clinical data that resides in fragmented, siloed systems today,” said Jason Brown, CEO of MRO. “Combining MRO’s leading clinical data exchange solutions and Q-Centrix’s clinical data management capabilities creates a category defining, fit for purpose platform, enabling high fidelity, low latency acquisition, abstraction, curation, and exchange of clinical data to power better patient care and reduce costs across the healthcare ecosystem.”
With a comprehensive clinical data management platform, providers, payers, and life sciences will be able to simplify complexity, accelerate decisions, and advance outcomes. By transforming clinical data from raw records into enriched, curated data assets, MRO and Q-Centrix create scalable value that supports more precise decision-making and broader clinical applications.
“MRO and Q-Centrix share a commitment to advancing the industry in service of our customers,” said Milton Silva-Craig, CEO at Q-Centrix. “That focus is fueling the creation of a first-of-its-kind platform—seamlessly integrating systems and delivering structured, highly valuable data sets to support clinical care, operational performance, breakthrough research, and regulatory compliance. Purpose-built around our customers’ most pressing needs, this is innovation where it matters most.”
The acquisition is supported by several leading healthcare technology investors, including Parthenon Capital, a growth-oriented private equity firm and an existing investor in MRO. As part of the transaction, Parthenon Capital made a significant new investment to support MRO’s growth over time. MRO is acquiring Q-Centrix from TPG Growth, the middle market and growth equity platform of global alternative asset management firm TPG.